Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 26, 2011 Brian Stoffel	5 Stocks Our Experts Are Buying Now An update on our Rising Star portfolios, with five of the most recent buys by our analysts, along with the thesis behind their purchases.
The Motley Fool August 10, 2011 Jim Mueller	Rising Star Buy: Digging Dendreon After getting hammered, there's an opportunity here.
The Motley Fool April 20, 2011 Jim Mueller	Rising Star Buy: Go Hertz The market hasn't quite caught up with this opportunity.
The Motley Fool August 4, 2011 Brian Orelli	Dendreon Down 65%! What's Next? What caused Dendreon's shocking collapse?
The Motley Fool August 31, 2010 Brian Orelli	What Is Dendreon Worth? Now that's a good question, isn't it?
The Motley Fool January 31, 2011 Jim Mueller	Rising Star Buy: SUPERVALU One of the most hated stocks may be an opportunity in disguise.
The Motley Fool August 8, 2011 Luke Timmerman	Dendreon Wounds Are Self-Inflicted, Not the Start of a Biotech Industry Virus Is Dendreon doomed?
The Motley Fool August 4, 2010 Brian Orelli	Dendreon Doubles Up The biotech enjoys twice as much revenue month over month.
The Motley Fool May 9, 2011 Rich Duprey	Car Rentals Are Ready for a Road Trip As takeover interest picks up for Dollar Thrifty, the auto rental business looks ready to hit the highway.
The Motley Fool September 1, 2010 Brian Orelli	Dendreon: One Step Closer to Worry-Free Back in July, the Centers for Medicare & Medicaid Services announced that it planned on reviewing the reimbursement for Dendreon's prostate cancer treatment Provenge.
The Motley Fool July 1, 2011 Luke Timmerman	Dendreon Sways Medicare to Pay for Prostate Cancer Drug The decision by Medicare is no surprise, but it does conclude a period of uncertainty about insurance reimbursement for its lone marketed product.
The Motley Fool April 15, 2011 Andrew Tonner	This Grocer Improves, But Not Enough SUPERVALU posts better results, but still struggles.
The Motley Fool June 30, 2011 Brian Orelli	Dendreon Increases Potential Output, More to Come Los Angeles plant is approved.
The Motley Fool December 16, 2011 Brian Orelli	Dendreon 2011: Supply Constrained to Missed Guidance A year in review for the biotech.
The Motley Fool November 3, 2011 David Williamson	Medivation Investors: Why Your Stock Just Jumped 140% Medivation shares pop on trial success for prostate cancer treatment MDV3100.
The Motley Fool August 4, 2010 Luke Timmerman	Dendreon Conference Call Notebook: The Tale of a Provenge Launch Ramp-Up What's working for Dendreon? How is its groundbreaking prostate cancer drug performing in its first few months on the market?
The Motley Fool November 4, 2010 Brian Orelli	Are Monthly Numbers Necessary, Dendreon? Focus on what's important.
The Motley Fool November 18, 2010 Brian Orelli	Worry-Free Dendreon? One step closer to national reimbursement from the Centers for Medicare and Medicaid Services to pay for its prostate cancer treatment Provenge.
The Motley Fool March 17, 2008 Brian Lawler	Parsing the Details With Dendreon Development-stage drugmaker Dendreon announces that it is changing its pivotal phase 3 clinical trial for its lead drug.
The Motley Fool March 2, 2011 Brian Orelli	When Will Dendreon Make Money? Not for awhile ... it's a biotech thing.
The Motley Fool August 11, 2011 Brian Orelli	Dendreon's a Broken IPO, Again $10 isn't really a magical number.
The Motley Fool July 1, 2010 Brian Orelli	Is Dendreon's Provenge in Trouble Before It Starts? Not! The Centers for Medicare & Medicaid Services questions the coverage of Provenge.
InsideFlyer December 2011	Hertz Status Match Frequent renters of cars who have elite status with Avis or National can request a status match from Hertz Gold Plus Rewards through Jan. 31, 2012.
The Motley Fool September 28, 2010 Brian Orelli	It's Up! It's Down! It's Dendreon! The joys of biotech.
The Motley Fool February 26, 2009 Chris Jones	It Only Hertz When I Cry The world's largest vehicle rental company felt the pain last quarter.
The Motley Fool July 12, 2007 Brian Lawler	Dendreon Under Attack Following an unfavorable regulatory decision for its lead drug Provenge, the biotech is now the focus of an SEC inquiry.
The Motley Fool June 14, 2005 Rich Smith	Ford's Painful Spinoff The company's Hertz unit is poised for an IPO. But what's good for Ford may not necessarily be a good thing for Hertz buyers.
The Motley Fool January 30, 2009 Rich Duprey	Rent-a-Bailout Is the Wrong Road to Take Letting car rental agencies have access to TARP funds is a wreck waiting to happen.
The Motley Fool January 10, 2008 Ron Vlieger	SUPERVALU Could Use More Green Profits rise at SUPERVALU, the third-largest food retailer in the country, but integrating Albertsons will take longer than expected.
The Motley Fool April 26, 2007 Mike Havrilla	Dendreon Is Worth a Shot Provenge might be approved, which means investors might be rewarded. However, the massive short interest also highlights the tremendous risk in Dendreon.
The Motley Fool October 5, 2009 Rick Aristotle Munarriz	Hertz So Good The car rental company fights back against a bankruptcy prediction.
The Motley Fool June 22, 2009 Jim Mueller	Dendreon: Cash Out or Keep Riding Up? Given Dendreon's rise this year and Provenge's prospects, what should a prudent investor do?
The Motley Fool August 9, 2010 Brian Orelli	Dendreon's in Trouble Provided you call a slap on the wrist from the FDA "trouble."
The Motley Fool January 10, 2006 Stephen D. Simpson	SUPERVALU's Split Personality The discount grocer attempts to operate several different concepts simultaneously. The stock responded well to the company's third-quarter earnings announcement, but it really wasn't all that great of a quarter.
The Motley Fool July 1, 2011 Brian Orelli	Dendreon Is Drama-Free ... for Now For a drug that has had so much drama during its existence, the final decision by the Centers for Medicare and Medicaid Services to pay for Dendreon's prostate cancer treatment Provenge was pretty anticlimactic.
The Motley Fool November 23, 2011 Brian Orelli	I Was Wrong About Dendreon But maybe not in the long term.
The Motley Fool October 15, 2008 Rich Duprey	One Not-So-Good Value This supermarket chain can't overcome the sour economy.
The Motley Fool January 7, 2011 Brian Orelli	Dendreon Heads Across the Pond A pathway to Provenge approval in the EU.
The Motley Fool November 3, 2011 Brian Orelli	Modest Growth, Less-Than-Modest Stock Drop Dendreon's investors aren't happy.
The Motley Fool April 29, 2009 Brian Orelli	2 Lessons From Dendreon Traders beware.
The Motley Fool August 29, 2011 Brian Orelli	We Can Make More! Too Bad Few Want It Dendreon is no longer constrained by its supply.
The Motley Fool November 30, 2010 Brian Orelli	Soros Is Buying Health Care. Should You? Some but not all of his picks look good to me.
The Motley Fool October 31, 2008 Brian Orelli	World's Scariest Stock: Dendreon The fear of the unknown makes investing scary, and things don't get much more unknown than the future of biotech company Dendreon.
The Motley Fool May 3, 2011 Brian Orelli	Brakes Are Off at Dendreon Ramping up sales, one month at a time.
The Motley Fool October 19, 2011 Brian Orelli	Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson.
The Motley Fool June 19, 2009 Brian Orelli	Dendreon Is No Dot-Com Story ... Yet Is Dendreon a bad buy at today's prices? Not if it gets cancer treatment Provenge approved. And there's the risk.
The Motley Fool May 10, 2006 Brian Lawler	Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note.
The Motley Fool June 1, 2007 Brian Lawler	Dendreon Gains. Why? Shares of the biopharma rise after it announces already expected news.
The Motley Fool May 14, 2007 Brian Lawler	Dendreon Tries to Pick Up the Pieces Dendreon lays out its preliminary plans following a negative FDA regulatory decision. Investors shouldn't necessarily take the smashed-down share price as indicative of a possible biotech value play.
The Motley Fool November 2, 2011 David Williamson	After Hours: Dendreon's Shares Crushed Again Bad guidance in third quarter earnings punishes this stock.